Abstract 679P
Background
LRB is a highly selective inhibitor of oncogenic transcription primarily metabolized by CYP3A4. This study investigated whether the PK and safety profile of LRB is affected by co-administration with ITZ, a strong CYP3A4 inhibitor, in adult patients with advanced solid tumors.
Methods
This was a 2-part crossover, open-label, phase Ib drug-drug interaction study (NCT05063318). In Part A, 3 patients were assigned to sequence 1 (TR) receiving a cycle (C) 1 of LRB (0.8 mg/m2, 1 hour [h], iv) co-administered with ITZ (200 mg/day oral; 12-days), followed by a C2 of LRB alone (3.2 mg/m2, 1 h, iv). In Part B, 11 patients were randomized (1:1) to receive either sequence 1 (TR) or 2 (RT). Plasma samples for LRB and ITZ PK were collected.
Results
11 patients were evaluable for the primary objective of the study: 3 patients in Part A and 8 patients in Part B (4 in each of sequences 1 and 2). The systemic exposure of LRB was increased [15% for Cmax, 2.4-fold for AUC0-t and 2.7-fold for AUC0-∞] with ITZ co-administration. This correlated with reduced clearance (CL) by 63% and prolonged elimination half-life (t1/2) by 2.2-fold. Co-administration with ITZ produced statistically significant modifications in the unbound plasma LRB PK parameters of similar extent than in total plasma with a 2.2-fold and 2.4-fold increase in AUC0-t and AUC0-∞, respectively compared to LRB alone. Unbound LRB CL decreased by 58% and t1/2 was 2-fold longer. Consistent with previous studies, the most common treatment-related adverse events of LRB alone at dose of 3.2 mg/m2 were neutropenia, nausea, vomiting and fatigue. Safety profile of LRB at a dose of 0.9 mg/m2 when co-administered with ITZ was no worse than that of LRB administered alone at 3.2 mg/m2.
Conclusions
In comparison with LRB alone, the co-administration with multiple doses of ITZ, significantly altered LRB systemic exposure reducing total plasma (by 63%) and unbound (by 58%) LRB CL. The magnitude of these changes showed a clinically relevant effect of ITZ co-administration on LRB PKs. To avoid LRB overexposure and a worst safety profile when co-administered with strong CYP3A4 inhibitors a LRB dose reduction proportional to CL reduction should be applied.
Clinical trial identification
NCT05063318.
Editorial acknowledgement
Legal entity responsible for the study
PharmaMar.
Funding
PharmaMar.
Disclosure
E. Calvo: Financial Interests, Personal, Advisory Board: Adcendo, Amunix, Anaveon, AstraZeneca, BMS, Janssen, MonTa, MSD, Nanobiotix, Nouscom, Novartis, Servier, TargImmune, T-knife, Chugai, Elevation Oncology, Ellipses Pharmacy, SyneosHealth, Genmab, Diaccurate; Financial Interests, Personal, Invited Speaker: OncoDNA, PharmaMar, Roche/Genentech; Financial Interests, Personal, Full or part-time Employment, Director, Clinical Research: HM Hospitales Group; Financial Interests, Personal, Full or part-time Employment, Medical Oncologist. Clinical Investigator. Director, Clinical Research: START Madrid-CIOCC (Centro Integral Oncológico Clara Campal); Financial Interests, Personal, Member of Board of Directors, External Independent member of Board of Directors: PharmaMar; Financial Interests, Personal, Ownership Interest: START, Oncoart Associated; Financial Interests, Personal, Steering Committee Member, Member of Data Monitoring Committee: BeiGene, Sanofi, Merus; Financial Interests, Personal, Steering Committee Member: Novartis; Non-Financial Interests, Other, Non-for-profit Foundation. President and co-founder: INTHEOS (Investigational Therapeutics in Oncological Sciences) non-for-profit Foundation; Non-Financial Interests, Advisory Role: PsiOxus; Non-Financial Interests, Other, Chair of the Independent Data Monitoring Committee: EORTC IDMC; Non-Financial Interests, Member of Board of Directors, Non-for-profit Foundation, trustee member: Non-for-profit Foundation PharmaMar; Non-Financial Interests, Advisory Role, Non-for-profit foundation: CRIS Cancer Foundation, non-for-profit ; Non-Financial Interests, Member: ASCO, ESMO, SEOM, EORTC. S. Fudio: Financial Interests, Personal, Stocks or ownership: PharmaMar. C. Kahatt, J. Iglesias, R.O. Calafati, L. Pérez Ramos, L. Montilla, A. Zeaiter, R. Lubomirov: Financial Interests, Stocks or ownership: PharmaMar. All other authors have declared no conflicts of interest.
Resources from the same session
710P - A retrospective study on the safety and adequacy of fresh biopsies for next generation sequencing in early-phase clinical trials
Presenter: Edoardo Crimini
Session: Poster session 17
711TiP - A phase I/II, first-in-human, open-label, dose-escalation study of TAK-186, an EGFR × CD3ε COBRA T cell engager, in adult patients with unresectable, locally advanced, or metastatic solid tumors
Presenter: Andrew Weickhardt
Session: Poster session 17
712TiP - A phase I/II multicenter, open-label, dose-escalation, safety, pharmacodynamic, and pharmacokinetic study of Q901 administered via intravenous infusion in adult patients with selected advanced solid tumors with a cohort expansion at the recommended phase II dose
Presenter: Angela Alistar
Session: Poster session 17
713TiP - A phase I study of PRT3789, a potent and selective degrader of SMARCA2 in patients with advanced or metastatic solid tumors and a SMARCA4 mutation
Presenter: Ibiayi Dagogo-Jack
Session: Poster session 17
714TiP - A phase Ia/Ib, first-in-human, dose-escalation study evaluating the safety, tolerability, and efficacy of IOS-1002, a LILRB1, LILRB2, and KIR3DL1 targeting HLA-derived fusion protein administered alone or in combination with a PD-1 antibody in patients with advanced solid tumors
Presenter: Stephen Luen
Session: Poster session 17
715TiP - ARTS-021-1001: Phase I/II study of ARTS-021, a potent, oral administrated, selective CDK2 inhibitor, in advanced or metastatic solid tumors
Presenter: Yan Wang
Session: Poster session 17
716TiP - DETERMINE: A pioneering UK precision medicine trial for rare cancers
Presenter: Gary Middleton
Session: Poster session 17
717TiP - An open-label, multicentre, dose-escalation, first-in-human phase I study to evaluate safety, tolerability and antineoplastic activity of OATD-02 (dual arginase 1 and arginase 2 inhibitor) in patients with selected advanced and/or metastatic solid tumors
Presenter: Marta Dudek
Session: Poster session 17
718TiP - DEKA-1 a dose-finding phase I trial: Observing safety and biomarkers using DK210 (EGFR) for inoperable locally advanced and/or metastatic EGFR+ tumors with progressive disease failing systemic therapy
Presenter: Elizabeth Moser
Session: Poster session 17
719TiP - A phase I/Ib study of the Werner (WRN) helicase inhibitor HRO761 as single agent and in combination with irinotecan or tislelizumab in patients with microsatellite instability-high (MSIhi) or mismatch repair deficient (dMMR) advanced solid tumors
Presenter: Michele Moschetta
Session: Poster session 17